Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 6Multiple Myeloma 5Prostatic Neoplasms 4Neoplasm Metastasis 4Myelodysplastic Syndromes 4Lung Neoplasms 4Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Biphenotypic, Acute 2Glioma 2Colorectal Neoplasms 2Osteosarcoma 1Opioid-Related Disorders 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neuroblastoma 1Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cytarabine 13Cyclophosphamide 11fludarabine 10Filgrastim 8fludarabine phosphate 7Methotrexate 7Vincristine 6Specimen Handling 5Dexamethasone 5Biopsy 5venetoclax 4revumenib 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Azacitidine 4Whole-Body Irradiation 3Prednisone 3Mycophenolic Acid 3Leucovorin 3Hydrocortisone 3Clofarabine 3selinexor 2merphos 2ixazomib 2blinatumomab 2aldesleukin 2X-Rays 2Vorinostat 2Topotecan 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Biphenotypic, Acute × X-Rays × Clear all
NCT07498465 2026-05-05

A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

Children's Oncology Group

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04375631 2026-03-05

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Fred Hutchinson Cancer Center

Phase 1 Recruiting
120 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡